// App-Quantinova.ai

: The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis

Researchers

Presenter

  • Stefano Molica

Principal Investigators

  • David Allsup

  • Aaron Polliack

  • Diana Giannarelli

Medical Centers

  • Department Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK, Department Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK, Hull, United Kingdom

  • Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, United Kingdom

  • Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy., Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy., Rome, Italy

  • Hadassah University Hospital and Hebrew University Medical School, Jerusalem, Israel

Locations

  • United Kingdom

  • Italy

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Chronic Lymphocytic Leukemia

  • Arrhythmia

  • Neutropenia

Biomarkers

  • Tumor protein p53

Drug/Treatment

  • ACP-196

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Venetoclax

  • Ibrutinib

  • TP53

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Active Comparator

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved